CompletedPhase 4

12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)

Sweden224 participantsStarted 2004-03-11

Plain-language summary

To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who have signed an written informed consent consistent with ICH GCP guidelines and local legislations prior to participation in the trial.
✓. Patients with a diagnosis of COPD. COPD is defined as a disease state characterised by the presence of airflow obstruction often due to chronic bronchitis or emphysema; the airflow obstruction is generally progressive, may be accompanied by airway hyperreactivity, and may be partially reversible.
✓. Patients 40 years of age or older without any restriction to sex.
✓. Patients who currently smoke or who are ex-smokers with a cigarette smoking history of \>10 pack-years.
✓. Patients who have a relatively stable airway obstruction (at least 4 weeks free of COPD exacerbations) with a post bronchodilator FEV1 ? 60% of predicted normal, a post bronchodilation FEV1 \< 70% of FVC, and a MRC symptom score minimum of 2 at Visit 1

Exclusion criteria

✕. Patients with a history of asthma, allergic rhinitis, atopy, or who have a total (absolute) blood eosinophil count ? 600 per mm3 (= 0.6 \* 109/L) of the first determination at Visit 1
✕. Patients with known moderate or severe renal insufficiency.
✕. Patients with a recent history (i.e., 6 months or less prior to Visit 1) of myocardial infarction.
✕. Patients with any unstable or life threatening cardiac arrhythmia, including patients with a newly diagnosed, clinically relevant arrhythmia on the electrocardiogram (ECG) performed at Visit 1 as well as patients with cardiac arrhythmia requiring an intervention (i.e., hospitalisation, cardioversion, pacemaker placement, and automatic implantable cardiac defibrillator (AICD) placement) or a change in drug therapy during the last year prior to Visit 1.
✕. Patients who regularly use oxygen therapy.
✕. Patients with known active tuberculosis.
✕. Patients with a history of cancer within the last 5 years. Patients with treated basal cell carcinoma are allowed.
✕. Patients with a history of life threatening pulmonary obstruction or a history of cystic fibrosis or clinically evident bronchiectasis.

What they're measuring

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment.

Timeframe: week 12

Trial details

NCT IDNCT00144196

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-07-25

View on ClinicalTrials.gov More Pulmonary Disease, Chronic Obstructive trials